H-Index
79
Scimago Lab
powered by Scopus
JCR
Clarivate
Analytics
12%
Acceptance
Rate
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST

Logo

Medical Science Monitor Basic Research
AmJCaseRep

Annals
ISI-Home

eISSN: 1643-3750

Editorial: SARS-CoV-2 mRNA Vaccines and the Possible Mechanism of Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT)

Dinah V. Parums

Science Editor, Medical Science Monitor, International Scientific Information, Inc., Melville, NY, USA

Med Sci Monit 2021; 27:e932899

DOI: 10.12659/MSM.932899

Available online: 2021-04-26

Published: 2021-04-26


ABSTRACT: During 2020 and 2021, the global pandemic of coronavirus disease 2019 (COVID-19) due to severe acute respi- ratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in high death rates and acute and chronic morbidity in all countries. The rapid development of new mRNA vaccines to SARS-CoV-2 brings hope that the spread of this virus can be controlled. The ChAdOx1 nCoV-19 vaccine developed by a collaboration between the University of Oxford and AstraZeneca showed efficacy in clinical trials, with a good safety profile. However, there have been recent reports of the rare development of thrombotic events in young women following vaccination with ChAdOx1 nCoV-19, particularly of the rare condition of cavernous sinus thrombosis. Studies have begun to in- vestigate whether antibodies to the SARS-CoV-2 spike cross-react with platelet factor 4 (PF4/CXLC4) and mim- ic autoimmune heparin-induced thrombocytopenia. This Medical Science Monitor Editorial aims to briefly update the current status of studies on a possible rare complication of using new mRNA vaccines to prevent COVID-19.

Keywords: Editorial, Thrombotic thrombocytopenic purpura, acquired, Adverse Drug Reaction Reporting Systems, platelet factor 4, vaccin, COVID-19, severe acute respiratory syndrome coronavirus 2

Errate:

ABSTRACT The Oxford-AstraZeneca vaccine, ChAdOx1 nCoV-19 (AZD1222), uses double-stranded DNA, while the Pfizer-BioNTech and Moderna vaccines include single-stranded RNA to encode the SARS-CoV-2 spike protein. Reference: Parums DV. Editorial: SARS-CoV-2 mRNA Vaccines and the Possible Mechanism of Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT). Med Sci Monit 2021; 27:e932899; 10.12659/MSM.932899


Back